These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 32255671)

  • 1. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
    Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
    Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Alpha Therapy with Thorium-227.
    Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
    Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
    Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
    Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Effect of a Mesothelin-Targeted
    Wickstroem K; Hagemann UB; Cruciani V; Wengner AM; Kristian A; Ellingsen C; Siemeister G; Bjerke RM; Karlsson J; Ryan OB; Linden L; Mumberg D; Ziegelbauer K; Cuthbertson AS
    J Nucl Med; 2019 Sep; 60(9):1293-1300. PubMed ID: 30850485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted thorium-227 conjugates as treatment options in oncology.
    Karlsson J; Schatz CA; Wengner AM; Hammer S; Scholz A; Cuthbertson A; Wagner V; Hennekes H; Jardine V; Hagemann UB
    Front Med (Lausanne); 2022; 9():1071086. PubMed ID: 36726355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
    Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
    Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns.
    Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
    Drug Dev Ind Pharm; 2017 Feb; 43(2):225-233. PubMed ID: 27628177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
    Böhnke N; Indrevoll B; Hammer S; Papple A; Kristian A; Briem H; Celik A; Mumberg D; Cuthbertson A; Zitzmann-Kolbe S
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):669-680. PubMed ID: 37882848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An efficient chelator for complexation of thorium-227.
    Ramdahl T; Bonge-Hansen HT; Ryan OB; Larsen S; Herstad G; Sandberg M; Bjerke RM; Grant D; Brevik EM; Cuthbertson AS
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4318-21. PubMed ID: 27476138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thorium chelators for targeted alpha therapy: Rapid chelation of thorium-226.
    Ferrier MG; Li Y; Chyan MK; Wong R; Li L; Spreckelmeyer S; Hamlin DK; Mastren T; Fassbender ME; Orvig C; Wilbur DS
    J Labelled Comp Radiopharm; 2020 Oct; 63(12):502-516. PubMed ID: 32812275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals.
    Zhou X; Dong L; Shen L
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34834087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in targeted alpha therapy for prostate cancer.
    De Vincentis G; Gerritsen W; Gschwend JE; Hacker M; Lewington V; O'Sullivan JM; Oya M; Pacilio M; Parker C; Shore N; Sartor O;
    Ann Oncol; 2019 Nov; 30(11):1728-1739. PubMed ID: 31418764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
    Lejeune P; Cruciani V; Berg-Larsen A; Schlicker A; Mobergslien A; Bartnitzky L; Berndt S; Zitzmann-Kolbe S; Kamfenkel C; Stargard S; Hammer S; Jørgensen JS; Jackerott M; Nielsen CH; Schatz CA; Hennekes H; Karlsson J; Cuthbertson AS; Mumberg D; Hagemann UB
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
    Wickstroem K; Hagemann UB; Kristian A; Ellingsen C; Sommer A; Ellinger-Ziegelbauer H; Wirnitzer U; Hagelin EM; Larsen A; Smeets R; Bjerke RM; Karlsson J; Ryan OB; Wengner AM; Linden L; Mumberg D; Cuthbertson AS
    Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):410-422. PubMed ID: 31255687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part II: purification of targeted thorium conjugates on cation exchange columns.
    Frenvik JO; Dyrstad K; Kristensen S; Ryan OB
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1440-1449. PubMed ID: 28402142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Alpha Therapy: Current Clinical Applications.
    Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
    Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
    Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
    Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
    Wickstroem K; Karlsson J; Ellingsen C; Cruciani V; Kristian A; Hagemann UB; Bjerke RM; Ryan OB; Linden L; Mumberg D; Brands M; Cuthbertson A
    Pharmaceuticals (Basel); 2019 Oct; 12(4):. PubMed ID: 31618864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Targeted Alpha Particle Therapy for Solid Tumors.
    Tafreshi NK; Doligalski ML; Tichacek CJ; Pandya DN; Budzevich MM; El-Haddad G; Khushalani NI; Moros EG; McLaughlin ML; Wadas TJ; Morse DL
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy.
    Deblonde GJ; Lohrey TD; Booth CH; Carter KP; Parker BF; Larsen Å; Smeets R; Ryan OB; Cuthbertson AS; Abergel RJ
    Inorg Chem; 2018 Nov; 57(22):14337-14346. PubMed ID: 30372069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.